natgillin/translations-raw huggingface dataset:
Compositions are also provided by the present invention that are toxic to target lepidopteran pests of corn plants. A composition of transgenic plant cells provided in the diet of a target lepidopteran insect pest, in which each transgenic corn plant cell comprises in its genome a polynucleotide corresponding to the sequence as set forth in both SEQ ID NO:1 and SEQ ID NO:2, along with the contiguous nucleotide sequence as set forth in SEQ ID NO:5 between SEQ ID NO:1 and SEQ ID NO:2, is effective for providing protection against lepidopteran insect infestation to a corn plant or corn plant cell, so long as the corn plant or cell is expressing Cry1A.105 and/or Cry2Ab2 from the expression cassettes contained within the contiguous nucleotide sequence. 
Postupak prema zahtjevu 4 nadalje obuhvaća: (c) odabiranje potomstva koje sadrži nukleotidne sekvence SEQ ID NO: 1 i SEQ ID NO: 2, pri čemu je navedeno odabrano potomstvo biljke kukuruza otporno na insekte, po mogućnosti odabirom spomenutog koraka (c) koji obuhvaća izlaganje navedene biljke dobivene u (b) reakciji amplifikacije nukleinskih kiselina, pri čemu potomstvo koje proizvodi amplikon sadrži najmanje jednu odabranu nukleotidnu sekvencu SEQ ID NO: 1 ili SEQ ID NO: 2, ili izlaganjem barem jednog spomenutog potomka biljke dobivenog u koraku (b) reakciji hibridizacije nukleinske kiseline, pri čemu se potomci hibridiziraju sa probom koja hibridizira pod strogim uvjetima s jednom ili više DNA sekvencom odabranom od SEQ ID NO:11SEQID NO: 2.
Preferably the electropolishing takes place in a galvanic bath composed of phosphoric acid and sulfuric acid. Preferably the polished surfaces are passivated with nitric acid. 
Postupak u skladu s patentnim zahtjevom 3 ili 4, naznačen time što se polirane površine pasiviziraju dušičnom kiselinom.
Wind generator according to Claim 1, characterized in that said membrane tank (10) is connected to a compressed-air supply source for inflation and deflation thereof. 
Vjetrogenerator temeljem zahtjeva 1, naznačen time što je navedeni spremnik s membranama (10) spojen s izvorom opskrbe komprimiranim zrakom za njegovo napuhivanje i ispuhivanje.
A compound of Formula (I) wherein 
Spoj formule (1) naznačen time, da
The pulverized active ingredient is suspended in Lauroglyko® (propylene glycol laurate, Gattefossé S. A., Saint Priest, France) and ground in a wet pulverizer to produce a particle size of about 1-3 um. 
Praškastu aktivnu tvar se suspendira u lauroglikolu" (propilen glikol laurat, Gattefosse S.A., Saint Priest, Francuska) i smrvi se u mlinu za mokro mljevenje na veličinu čestica od približno 1-3 um.
bixafen and prothioconazole as active compounds. 
Kombinacije aktivnih spojeva koje kao aktivne spojeve sadrže
A compound of formula (I) or a physiologically acceptable solvate thereof for use in the treatment of patients according to claim 4, wherein the inflammatory and/or allergic condition is selected from eczema, psoriasis, allergic dermatitis, neurodermatitis, pruritis, hypersensitivity reactions, asthma, rhinitis, nasal polyps, chronic obstructive pulmonary disease, interstitial lung disease, fibrosis, ulcerative colitis, Crohn's disease, rheumatoid arthritis and conjunctivitis. 
Spoj formule (I), ili njegov fiziološki prihvatljiv solvat, u skladu s patentnim zahtjevom 12, naznačen time što je namijenjen upotrebi u liječenju pacijenata s ekcemom, psorijazom, alergijskim dermatitisom, neurodermatitisom, svrbežom, reakcijama preosjetljivosti, astmom, rinitisom, polipima u nosu, kroničnom opstruktivnom plućnom bolešću, intersticijskom plućnom bolešću, fibrozom, ulceroznim kolitisom, Crohnovom bolešću, reumatoidnim artritisom i lonjunktivitisom.
The composition claim 9, wherein said at least 80% of said placental stem cells express OCT-4. The composition of any one of claims 1-8, wherein at least 90% of said placental stem cells express CD73, CD105, and CD200. 
Izdvojena populacija matičnih stanica iz posteljice u skladu s patentnim zahtjevom 14, naznačena time što navedenih najmanje 80% od navedenih matičnih stanica iz posteljice eksprimira CD73, CD105 i CD200.
a 3' homology arm that is homologous to a 3' target sequence at the genomic locus of interest, wherein the pluripotent cell is a non-human mammalian pluripotent cell or a human induced pluripotent stem cell, and wherein following contacting the pluripotent cell with the Cas9 protein, the CRISPR RNA, the tracrRNA, and the LTVEC, the genome of the pluripotent cell is modified to comprise a targeted genetic modification comprising deletion of a region of the genomic locus of interest wherein the deletion is at least 30 kb and/or insertion of the insert nucleic acid at the genomic locus of interest wherein the insertion is at least 30 kb. 
(i) 5 homologonu ruku koja je homologna s 5* ciljnom sekvencom na genomskom lokusu od interesa; i (1i) 3 homologom rukom koja je homologna s 3? ciljnom sekvencom na genomskom lokusu od interesa, naznačeno time da nakon dovođenja u kontakt mišje ES stanice s Cas9 proteinom, CRISPR RNA, 1 tracrRNA u prisustvu LTVEC, genom mišje ES stanice je modificiran tako da obuhvaća ciljnu genetičku modifikaciju koja obuhvaća deleciju područja genomskog lokusa od interesa gdje je delecija najmanje 30 kb i/ili insercija inserta nukleinske kiseline na genomskom lokusu od interesa naznačeno time da je insercija najmanje 30 kb.
The formulation of anyone of claims 1 to 5 wherein the salt in the pH buffered saline solution is sodium chloride. 
Formulacija u skladu s patentnim zahtjevom 21, naznačena time što sol u fiziološkoj otopini s puferiranim pH sadrži natrijev klorid.
The device of claim 1, wherein the device further includes a clip affixed to the device, wherein the clip is effective to clip the device onto an object, and wherein preferably the clip is located on the removable cap. 
Uređaj prema zahtjevu 1, naznačen time, da uređaj dodatno obuhvaća kvačicu (110) pričvršćenu na uređaj, pri čemu je kvačica učinkovita za zakvačenje uređaja na neki objekt, i pritom je kvačica poželjno smještena na premjestivoj kapici (112).
Fig. 1 shows a longitudinal section through a pharmaceutical vial and a closure made of elastomer material of this invention. 
Slika 1 prikazuje uzdužni presjek kroz farmaceutsku bočicu i kroz zatvarač koji je načinjen od elastomernog materijala iz ovog izuma.
The process of para 1 or any one of paras 2-5, wherein the functional filler is present in an amount ranging from about 50% to about 70% by weight of the waste polymer. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što funkcionalno punilo dolazi u rasponu količina od 50% do 70%, težinski, otpadnog polimera.
A compound according to claim 1 wherein R1 represents C1-8 alkyl or C3-8 cycloalkyl-C0-6 alkyl, wherein any alkyl group may be optionally substituted with one or more halogen groups and the C3-8 cycloalkyl group may be optionally substituted with one or more substituents independently selected from C1-4 alkyl, halogen and aryl; preferably R1 represents C1-8 alkyl or C3-8 cycloalkyl-C0-6 alkyl; more preferably R1 represents C4-6 alkyl or C3-8 cycloalkyl-C0-1 alkyl; and still more preferably R1 represents isobutyl, 2,2-dimethylpropyl, cyclobutyl, cyclopentyl cyclohexyl, cyclohexylmethyl or cyclopropylmethyl. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da R1 predstavlja C1-8 alkil ili C3-8 cikloalkil-C0-6 alkil, pri čemu bilo koja alkilna skupina po izboru može biti supstituirana s jednom ili više skupina halogena i C3-8 cikloalkilna skupina po izboru može biti supstituirana s jednim ili više supstituenata neovisno odabranih od C1-4 alkila, halogena i arila; poželjno je da R1 predstavlja C1-8 alkil ili C3-8 cikloalkil-C0-6 alkil; još poželjnije da R1 predstavlja C4-6 alkil ili C3-8 cikloalkil-C0-1 alkil; a još je više poželjno da R1 predstavlja izobutil, 2,2-dimetilpropil, ciklobutil, ciklopentil cikloheksil, cikloheksilmetil ili ciklopropilmetil.
providing said bottom ash into a rotating cylindrical body having a plurality of nozzles for spraying a regeneration fluid along length of cylindrical body; 
dobavu navedenog pepela s dna peći (17) u rotirajuće cilindrično tijelo (110) koje ima mnoštvo mlaznica (131) za raspršivanje regeneracijskog fluida po duljini cilindričnog tijela (110);
Traditionally, breathable shoes are shoes that use natural materials such as leather or equivalent products, which however, in the presence of rain or bad weather, indeed because of their permeation properties, do not ensure good waterproofness and indeed absorb water rather easily. 
Tradicionalno se u prozračnim cipelama koriste prirodni materijali poput kože ili jednakovrijednih proizvoda, koji za kišovitog ili lošeg vremena, uglavnom zbog svojstava vodopropusnosti, ne osiguravaju dovoljan stupanj vodootpornosti i prilično brzo apsorbiraju vodu.
In some embodiments, examples of a perfluoroalkyl include, but not limited to, trifluoromethyl, pentafluoroethyl, heptafluoropropyl, 1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl, and the like. 
U nekim oblicima perfluoroalkil uključuju, ali nisu ograničeni na,trifluorometil, pentafluoroetil heptafluoropropil, 1,2,2,2-tetrafluoro-1-trifluorometil-etil, te slično.
The process of any one of claims 1-8 containing a further step of mixing the conjugate with further antigens optionally wherein the further antigens comprises at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 S.pneumoniae saccharides selected from the group consisting of 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F and 33F. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1-8, naznačen time što uključuje dodatni korak miješanja konjugata s dodatnim antigensom, gdje dodatni antigeni može uključivati u najmanju ruku 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 ili 20 S. pneumoniae saharide, koji se biraju iz skupine koju čine 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F i 33F.
The method of embodiments 29, further comprising, prior to (c), computationally removing allele frequencies for polymorphisms identified has being heterozygous in the pregnant individual. The method of embodiment 29, wherein the mixture model accounts for sequencing error. The method of embodiment 29, wherein the DNA obtained from a bodily fluid of a pregnant individual is cell-free DNA obtained from the plasma of the pregnant individual. 
Postupak prema patentnim zahtjevima 1, naznačen time što nadalje sadrži, prije postupka (c), računalno uklanjanje učestalosti alela za polimorfizme koji su identificirani kao heterozigotni kod trudne osobe. Postupak prema patentnom zahtjevu 1, naznačen time što model vjerojatnosti distribucije u mješavini uračunava grešku sekvenciranja.
The pharmaceutical composition according to claim 13, wherein the pharmaceutical composition is in a form suitable for oral administration to a mammal. 
Farmaceutski pripravak prema zahtjevu 7, naznačen time da je navedeni farmaceutski pripravak u obliku pogodnom za oralno davanje sisavcu.
The set of panels as recited in any of the preceding embodiments, wherein the panels are provided with a locking element (12) and a locking groove (14) for locking the panels parallel to the main plane (MP) of the first panel (1). 
Komplet dijelova namještaja prema bilo kojem od prethodnih zahtjeva, naznačen time da su ploče opremljene elementom za zabravljivanje (12) i zapornim utorom (14) za zaključavanje ploča paralelnih s glavnom ravninom (MP) prve ploče (1).
The compound for use according to claim 19, wherein the cancer is leukemia. 
Spoj za uporabu u sklađu s patentnim zahtjevom 19, naznačen time što je rak leukemija.
A composition comprising a combination of (i) at least one inhibitor of platelet aggregation selected from clopidogrel, cilostazol, ticlopidine, and tirofiban and (ii) a compound selected from mecamylamine, irbesartan, idraparinux, otamixaban, and SR48692, or salts or prodrugs or derivatives or sustained release formulations thereof, for use in the treatment of multiple sclerosis (MS). 
Sastav sadrži (i) najmanje jednu tvar odabranu između klopidogrela, cilostazola, tikolopidina, ili tirofibana, u kombinaciji s (ii) jednom tvari odabranom između mekamilamina, irbesartana, idraparinuksa ili otamiksabana, ili njihovih soli ili formulacija za postepeno oslobađanje za uporabu u liječenju multiple skleroze (MS).
a transceiver configured to transmit and receive a signal over a network; and 
odašiljača konfiguriranog za prijenos kontrolnog signala uporabom frekvencijskog resursa; i upravljačkog uređaja konfiguriranog za:
wherein A, B, C, and D are reactive moieties each containing one or more charges, wherein each of the A, B, C, and D reactive moieties independently contain a moiety selected from the group consisting of a vinyl sulfone, an acrylate group, a methacrylate group, a styrene group, an acryl amide group, a methacryl amide group, a maleate group, a fumarate group, and an itaconate group; 
A, B, €, 1 D su reaktivni dijelovi koji su u stanju reagirati sa slobodnim tiolnim skupinama od kojih svaki sadrži jedan ili više naboja, gdje svaki od reaktivnih dijelova A, B, €, i D neovisno sadrži dio odabran iz skupine koju čine vinil sulfon, akrilatna skupina, metakrilatna skupina, stiren skupina, akrilamidna skupina, metakrilamidna skupina, maleatna skupina, fumaratna skupina, i itakonska skupina;
comparing said received reflected pulse of output ultrasonic vibrations with a previously detected pulse of output ultrasonic vibrations reflected from said distal surface of said wall and received at said proximal surface to detect changes in said surface of said wall, wherein said received reflected pulse of output ultrasonic vibrations and said previously detected pulse of output ultrasonic vibrations comprise vibrations reflected from said distal surface of said wall in response to different pulses of input ultrasonic vibrations; and 
usporedbu (46) navedene primljene ultrazvučne vibracije s prethodno detektiranim impulsom izlaza ultrazvučnih vibracija reflektiranim od navedene distalne površine navedene stjenke i primljenim na navedenoj proksimalnoj površini radi otkrivanja promjena u navedenoj površini navedene stjenke.
Multiparticulates according to claim 12, wherein the percentage amounts of the ingredients (a) to (e) are as given in the following table, based on the total weight of the five ingredients: oxycodone as hydrochloride 
Višečestični oblici prema patentnom zahtjevu 12, naznačeni time što su procentne količine sastojaka (a) do (e) kao što su navedene u slijedećoj tabeli, na osnovu ukupne težine pet sastojaka: oksikodon kao hidroklorid
each outer air duct (50) is arranged adjacent to respective one or more cooling fins (40), 
- svaki vanjski vod za zrak (50) se nalazi uz odgovarajuće jedno il1 više rashladnih rebara (40),
A pharmaceutical composition according to claim 8, for improvement of motor functions, cognitive functions and related emotional disturbances, and after brain injury induced by traumatic, inflammatory, infectious, neoplastic, vascular, hypoxic or metabolic causes or brain injury induced by toxic reactions to exogenous chemicals, wherein the exogenous chemicals are selected from the group consisting of substances of abuse, pharmaceutical compounds, environmental toxins. 
Farmaceutski pripravak prema zahtjevu 8, naznačen time, što je za poboljšanje motoričkih funkcija, kognitivnih funkcija i srodnih emocionalnih poremećaja, a nakon ozljede mozga induciran traumatskim, upalnim, infektivnim, neoplastičnim, vaskularnim, hipoksičkim ili metaboličkim uzrocima ili ozljeda mozga inducirana toksičnim reakcijama na egzogenim kemikalijama, pri čemu su egzogene kemikalije odabrane iz skupine koja se sastoji od zloupotrebe supstance, farmaceutskih spojeva, toksina okoliša,
The coating material as recited in claim 1, wherein the hydroxy-functional binder component comprises from 10 to 30 vol % of the glass hollow bodies based on a total volume of the hydroxy-functional binder component. 
Obložni materijal prema jednom od prethodnih zahtjeva, naznačen time, da vezivna komponenta ima od 10 do 30 volumenskih %, poželjno od 15 do 25 volumenskih %, posebno poželjno od 16 do 20 volumenskih % staklenog šupljeg tijela, na bazi ukupnog volumena vezivne komponente.
A compound having the formula: 
Spoj s formulom:
Cup as claimed in one of the preceding claims, characterized in that the wall section (4) is rigid. 
Spremnik prema jednom od prethodnih patentnih zahtjeva, naznačen time da je dio stijenke (4) krut.
The lid according to claim 14, wherein the first plastic material is General Purpose Polystyrene (GPPS). The lid according to claim 15, wherein the second plastic material is High Impact Polystyrene (HIPS). The lid according to claim 16, wherein the first material participates in the mixture with a percentage of 30-50%, while the second material participates in the mixture with a percentage of 50-70%. 
Poklopac prema jednom od prethodnih patentnih zahtjeva, naznačen time da je materijal poklopca (5) mješavina iz barem prvog plastičnog materijala i drugog plastičnog materijala, pri čemu prvi materijal ima veću krutost nego drugi materijal, i da prvi materijal u mješavini sudjeluje u postotku 30 - 50 %, dok drugi materijal sudjeluje u mješavini s postotkom 50 - 70 %.
This invention also relates to compounds of Formula (I)(A), wherein A is a 6-membered heterocyclic ring, which may contain 0-3 double bonds and may be substituted by 1 to 3 groups selected from the group consisting of C1-C6alkyl, substituted C1-C6alkyl, C3-C7cycloalkyl, halo, hydroxyl, oxo, amide, carboxylic acid, —C(O)Ra, —SO2Ra, arylalkyl, —(C1-C3alkyl)aryloxy, aryl, heteroaryl and C1-C4alkoxy, in which each Ra is independently C1-C6alkyl, substituted C1-C6alkyl or unsubstituted C3-C7cycloalkyl; each R2 and R3 is independently hydrogen, C1-C6alkyl, substituted C1-C6alkyl, halo, hydroxyl, amide, carboxylic acid or C1-C4alkoxy; 
Spoj u skladu s patentnim zahtjevom 2, naznačen time što je A 6-eročlani heterociklički prsten, koji može sadržavati 0-3 dvostruke veze i može biti supstituiran s 1 do 3 skupine, koje se bira iz skupine koju čine C;-Cgalkil, supstituirani C;-Cgalkil, C3-Czcikloalkil, halogen, hidroksil, okso, amid, karboksilna kiselina, -C(O)R,, -SO>R., arilalkil, (C,-Csalkiljariloksi, aril, heteroaril i Ci-Cu,alkoksi, gdje je svaki R, neovisno C,-Csalkil, supstituirani C;-Csalkil ili nesupstituirani C3-C;cikloalkil; svaki R> i Rz je neovisno vodik, C,-Cgalkil, supstituirani C,-Cgalkil, halogen, hidroksil, amid, karboksilna kiselina ili Ci-C,alkoksi;
Clause 15. The method of Clause 1, wherein the adjuvant is selected from the group consisting of 3D-MPL and QS21 in a liposome formulation and 3D-MPL and QS21 and an oil in water emulsion. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time što se adjuvans bira iz skupine koju čine 3D-MPL i QS21 u liposomskoj formulaciji i 3D-MPL, QS21 i emulzija tipa ulje u vodi.
The method according to claim 8, wherein the first dose is equal to the minimum of (Cont/n) and at least one ceiling value and the second dose is equal to the maximum of (Cont/(n+D) and at least one bottom value, where n is equal to INT (Cont/D) and Cont is the current content of the medication container. 
Metoda u skladu s bilo kojim od zahtjeva 8 do 10 naznačena time da je prva doza jednaka minimumu (Cont/n) i najmanje jednom plafonskoj vrijednosti a druga doza je jednaka maksimumu (Cont(n+1)) i najmanje jednoj najnižoj vrijednosti gdje je n jednako INT (Cont/D) a Cont predstavlja trenutni sadržaj spremnika lijekova.
Z represents a capture tag which is a long-chain alkyl residue, a perfluoroalkyl entity, an azide or an alkynyl group, 
Z predstavlja oznaku za hvatanje, koja je Cg_24 alkilni ostatak, perfluoroalkil skupina, azid ili alkinil skupina,
A hybrid nuclease molecule comprising a first nuclease domain and a modified Fc domain, wherein the first nuclease domain is operatively coupled to the Fc domain and wherein the Fc domain is modified such that the molecule has reduced cytotoxicity relative to a hybrid nuclease molecule having an unmodified Fc domain. A hybrid nuclease molecule comprising an amino acid sequence set forth in SEQ ID NO: 62, 64, 78, 80, 92, or 96, or a hybrid nuclease molecule comprising an amino acid sequence at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 62, 64, 78, 80, 92, or 96. 
HR P20180564 T1 PATENTNI ZAHTJEVI Molekula hibridne nukleaze koja sadrži ljudsku RNazu i mutant ljudske IgGI Fc domene, pri čemu je ljudska RNaza operativno vezana na Fc domenu i pri čemu Fc domena uključuje mutaciju P238S 1 mutaciju P331S i ima smanjenu citotoksičnost u odnosu na hibridnu molekulu nukleaze koja ima nemodificiranu Fc domenu, te pri čemu molekula hibridne nukleaze sadrži: sekvencu aminokiseline navedenu u SEQ ID NO: 96, 92, 62 ili 78; ili sekvencu aminokiseline navedenu u SEQ ID NO: 98 ili 94.
The method of claim 91, wherein the peptide has an amino acid sequence consisting of SEQ ID NO:69. 
Himerni peptid sukladno zahtjevu 1, naznačen time što se sastoji od SEQ ID NO:69.
A too high dose of some polyols may have similar effects. 
Slične učinke ima i prevelika doza nekih poliola.
Apparatus according to claim 1 wherein the controller switches operation of the apparatus between flush and maintenance modes at regular intervals. Apparatus according to claim 11 wherein duration of a period of operation in the flush mode is the same for each of a plurality of consecutive periods of operation in the flush mode. 
Uređaj prema bilo kojem od prethodnih zahtjeva, pri čemu kontrolor vrši prebacivanje rada uređaja između radnog režima ispiranja i radnog režima održavanja u regularnim intervalima, pri čemu je trajanje perioda rada u radnom režimu ispiranja isto za mnoštvo uzastopnih perioda rada u radnom režimu ispiranja.
obtaining (S547) the PLP from the signal frame using the layer-1 information. 
analiziranja okvira signala od primljenog signala ln nn na na nn nn
electrically driving (209) the active load (50) so as to at least reduce the current flowing in the active load (50) at the end of the validation of the candidate signal (Sc). 
električnom pogonjenju (209) aktivnog tereta (50) kako bi u najmanju ruku oslabio struju koja ide u aktivni teret (50) na kraju provjere kandidatnog signala (S).
In this discharge state, the user can depress and release the actuation member 17 as many times as desired to discharge the liquid 4 from the metering chamber 6 discontinuously or in respective steps. 
U tom stanju pražnjenja, korisnik može pritisnuti i rasteretiti element za pokretanje 17 toliko puta koliko želi da isprazni tekućinu 4 iz odmjerne komoru 6 s prekidima ili u dotičnim koracima.
is hydrogen, trichloromethyl, trifluoromethyl, halogen and cyano; or a pharmaceutically acceptable salt thereof. 
R1 je vodik, triklormetil, trifluormetil, halogen i cijano.
Use of a compound as claimed in claims 1-3 as an intermediate in the synthesis of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide (I) or a pharmaceutically acceptable salt thereof. 
Upotreba spoja kako je prijavljen u patentnim zahtjevima 1 – 3 kao međuprodukt u sintezi 6-(7-((1-aminociklopropil)metoksi)-6-metoksikinolin-4-iloksi)-N-metil-1-naftamida (I) ili odgovarajuće farmaceutski prihvatljive soli.
The magnetic dipole far-field, corresponding to the locally produced N-S-N (respectively S-N-S) transitions, decreases noteworthy with the third power of the distance. 
Daleka zona magnetskog dipola, koja odgovara lokalno proizvedenim prijelazima N-S-N (odnosno, S-N-S), značajno se smanjuje s trećom potencijom udaljenosti.